Related Experiment Video
Updated: Jan 7, 2026
Author Spotlight: Unraveling the Molecular Mechanisms in PCO and Fibrosis Following Cataract Surgery
Published on: December 1, 2023
A Large-Scale Cohort Analysis of Topical Prostaglandin Analog Use and Pseudophakic Cystoid Macular Edema Following
Jawad Muayad1, Ali O Mukhtar2, Darius D Bordbar2
1College of Medicine, Texas A&M University, Houston, Texas.
Purpose:
To evaluate whether perioperative topical prostaglandin analog (PGA) use alters the risk of pseudophakic cystoid macular edema (PCME) following routine cataract surgery.
Design:
A retrospective cohort study.
Participants:
Patients undergoing cataract surgery, without pre-existing high-risk factors for PCME (such as prior cystoid macular edema, uveitis, or retinal vascular diseases), categorized into three perioperative PGA exposure groups: (1) PGA prescribed within 3 months prior to surgery ("PGA Before"), (2) PGA prescribed within 1 month after surgery ("PGA After"), and (3) PGA prescribed both before and after surgery ("PGA Before & After"). The control group included patients with no PGA prescriptions any time before and 3 months after surgery.
Methods:
The data were collected from the TriNetX United States Collaborative Network. Propensity score matching was conducted to balance demographics, cataract type and surgical complexity, glaucoma type and severity, comorbidities, and concomitant topical and long-term systemic anti-inflammatory medication use between groups. Hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated to assess the 3-month risk of PCME following cataract surgery.
Main Outcome Measures:
Three-month incidence of diagnostically significant PCME following cataract surgery.
Results:
After matching, 9457 patients were included in the "PGA Before" group and its control, 1993 patients in the "PGA After" group and its control, and 2367 patients in the "PGA Before & After" group and its control. No significant difference in the risk of PCME was observed among those prescribed PGA prior to surgery (HR 1.08, 95% CI: 0.89-1.31), after surgery (HR 1.08, 95% CI: 0.68-1.70), or both before and after surgery (HR 0.86, 95% CI: 0.61-1.23), compared to matched controls.
Conclusions:
Perioperative PGA use before or after cataract surgery was not associated with an increased risk of PCME. These findings provide evidence that PGA use in the perioperative period may not significantly impact the risk of PCME within 3 months postsurgery.
Financial Disclosure(S):
Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
More Related Videos
04:59Author Spotlight: Enhancing Visual Outcomes in Cataract Surgery: A Novel Technique to Prevent Posterior Capsular Opacification Through IOL Rotation
Published on: July 7, 2023
06:19Author Spotlight: A Novel Protocol for Intracameral Injections to Enhance Precision in Rodent Ophthalmology
Published on: May 31, 2024
